Locations:
SearchOral immunotherapy drug is first of its kind
About 8% of U.S. children have a food allergy, and that number is on the rise. Avoiding the allergic trigger is recommended, but it’s not always possible.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Desensitization therapy, while not a cure, may alleviate some fear of accidental exposure by training the immune system to adapt.
In September 2019, an FDA expert panel recommended approval of a first-of-its-kind treatment — an oral immunotherapy medication to gradually build tolerance to peanut exposure.
In this video, learn more about why this therapy for peanut allergies is one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.
Advertisement
Advertisement
Cleveland Clinic and IBM leaders share insights, concerns, optimism about impacts
Cleveland Clinic will offer rapid, pinpoint airborne transport of medications and other medical items
$50 million pledge will help remove sources of lead exposure from Cleveland homes
The spine surgeon will oversee more than 125 staff physicians in his new role
Merlino rejoins Cleveland Clinic to help execute bold strategic vision
Reduces muscle pain caused by cholesterol-lowering drugs
FDA makes MitraClip available to more patients with mitral regurgitation
Tafamidis is first FDA-approved drug to treat potentially fatal disease